BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 21919599)

  • 21. Company profile: Sequenom, Inc.
    Cantor CR
    Pharmacogenomics; 2012 Apr; 13(5):529-31. PubMed ID: 22462745
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The future of psychiatric pharmacogenomics.
    Lohoff FW
    Pharmacogenomics; 2011 Jul; 12(7):927-9. PubMed ID: 21787185
    [No Abstract]   [Full Text] [Related]  

  • 23. Achieving the promise of personalized medicine.
    Reynolds KS
    Clin Pharmacol Ther; 2012 Oct; 92(4):401-5. PubMed ID: 22992663
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Time to adapt.
    Nature; 2010 Apr; 464(7293):1245-6. PubMed ID: 20428115
    [No Abstract]   [Full Text] [Related]  

  • 25. Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice.
    Squassina A; Manchia M; Manolopoulos VG; Artac M; Lappa-Manakou C; Karkabouna S; Mitropoulos K; Del Zompo M; Patrinos GP
    Pharmacogenomics; 2010 Aug; 11(8):1149-67. PubMed ID: 20712531
    [TBL] [Abstract][Full Text] [Related]  

  • 26. From personalized medicine to personalized justice: the promises of translational pharmacogenomics in the justice system.
    Wong SH; Happy C; Blinka D; Gock S; Jentzen JM; Donald Hon J; Coleman H; Jortani SA; Lucire Y; Morris-Kukoski CL; Neuman MG; Orsulak PJ; Sander T; Wagner MA; Wynn JR; Wu AH; Yeo KT
    Pharmacogenomics; 2010 Jun; 11(6):731-7. PubMed ID: 20504247
    [No Abstract]   [Full Text] [Related]  

  • 27. Pharmacy benefit managers, pharmacies, and pharmacogenomic testing: prescription for progress?
    Topol EJ
    Sci Transl Med; 2010 Aug; 2(44):44cm22. PubMed ID: 20702854
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Establishing clinical utility of pharmacogenetic tests in the post-FDAAA era.
    Evans BJ
    Clin Pharmacol Ther; 2010 Dec; 88(6):749-51. PubMed ID: 21081943
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acceptance of biomarker-based tests for application in clinical practice: criteria and obstacles.
    Pirmohamed M
    Clin Pharmacol Ther; 2010 Dec; 88(6):862-6. PubMed ID: 20981006
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cancer drugs find a companion with new diagnostic tests.
    Schubert C
    Nat Med; 2011 Oct; 17(10):1157. PubMed ID: 21988963
    [No Abstract]   [Full Text] [Related]  

  • 31. [Personalized treatment of cancer: utopia or chance?].
    Thiel E
    Dtsch Med Wochenschr; 2010 Sep; 135(38):1851. PubMed ID: 20842603
    [No Abstract]   [Full Text] [Related]  

  • 32. Crunch time for multiple-gene tests.
    Gewin V
    Nature; 2007 Jan; 445(7126):354-5. PubMed ID: 17251949
    [No Abstract]   [Full Text] [Related]  

  • 33. Personalized medicine prompts push to redesign clinical trials.
    Singer E
    Nat Med; 2005 May; 11(5):462. PubMed ID: 15875041
    [No Abstract]   [Full Text] [Related]  

  • 34. Ancestry, ancestry-informative markers, asthma, and the quest for personalized medicine.
    Barnes KC
    J Allergy Clin Immunol; 2010 Dec; 126(6):1139-40. PubMed ID: 21134571
    [No Abstract]   [Full Text] [Related]  

  • 35. [Introductory remarks by chairpersons].
    Kumagai S; Nobori T
    Rinsho Byori; 2013 May; 61(5):419-20. PubMed ID: 23947181
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Special report: companion diagnostics--example of BRAF gene mutation testing to select patients with melanoma for treatment with BRAF kinase inhibitors.
    Technol Eval Cent Assess Program Exec Summ; 2011 Nov; 26(7):1-5. PubMed ID: 22724160
    [No Abstract]   [Full Text] [Related]  

  • 37. Should pharmacogenomic studies be required for new drug approval?
    Relling MV; Hoffman JM
    Clin Pharmacol Ther; 2007 Mar; 81(3):425-8. PubMed ID: 17339872
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regulation and the fate of personalized medicine.
    Greenbaum D
    Virtual Mentor; 2012 Aug; 14(8):645-52. PubMed ID: 23351321
    [No Abstract]   [Full Text] [Related]  

  • 39. The promise of personalized medicine: regulatory controls and tort influences in the context of personalized risks and benefits.
    Prebula RJ
    J Contemp Health Law Policy; 2010; 26(2):343-72. PubMed ID: 20662360
    [No Abstract]   [Full Text] [Related]  

  • 40. Precision medicine in the age of big data: The present and future role of large-scale unbiased sequencing in drug discovery and development.
    Vicini P; Fields O; Lai E; Litwack ED; Martin AM; Morgan TM; Pacanowski MA; Papaluca M; Perez OD; Ringel MS; Robson M; Sakul H; Vockley J; Zaks T; Dolsten M; Søgaard M
    Clin Pharmacol Ther; 2016 Feb; 99(2):198-207. PubMed ID: 26536838
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.